Galvus Unia Europejska - polski - EMA (European Medicines Agency)

galvus

novartis europharm limited - wildagliptyna - diabetes mellitus, type 2 - leki stosowane w cukrzycy - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Jalra Unia Europejska - polski - EMA (European Medicines Agency)

jalra

novartis europharm limited - wildagliptyna - diabetes mellitus, type 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 dla dostępnych danych o różnych kombinacjach).

Xiliarx Unia Europejska - polski - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - wildagliptyna - diabetes mellitus, type 2 - leki stosowane w cukrzycy - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 dla dostępnych danych o różnych kombinacjach).